Salmeterol post-marketing surveillance: ethical issues

Publisher Website
Google Scholar
Abstract
Salmeterol is a long-acting β2 adrenoceptor agonist for inhalation which was introduced last December (Serevent - Allen & Hanburys/ Glaxo). In a preliminary review we concluded that it seemed useful for asthmatics who have symptoms despite conventional treatment including full prophylaxis.1 This article discusses Glaxo’s nationwide surveillance study of salmeterol2 which raises some important issues.

This publication has 0 references indexed in Scilit: